This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Beyonttra Banner.

Recorded webinars

ATTR-CM Masterclass Series

Recorded 2026

Session 1
 |  
Session 2 & 3
|  
Session 4 & 5

"ATTR-CM Masterclass Series" featuring Prof. Carsten Tschöpe

Welcome to the "ATTR-CM Masterclass Series" featuring Prof. Carsten Tschöpe, a distinguished expert in cardiac amyloidosis. This comprehensive series is designed to provide healthcare professionals with an in-depth understanding of transthyretin amyloid cardiomyopathy (ATTR-CM). Prof. Tschöpe will cover essential topics ranging from the fundamentals of ATTR-CM to the latest advancements in treatment and management strategies.
 

The

5 separate sessions
can be viewed below.

Professor Carsten Tschöpe

Professor Carsten Tschöpe_photo

Professor of Medicine and Cardiology, Charité University Hospital Berlin

Session 1: What is ATTR-CM vs AL?

  • In this opening section, Prof. Tschöpe clarifies the differences between Transthyretin Amyloidosis (ATTR) vs Light Chain Amyloidosis (AL). He discusses the mechanisms behind each condition and how understanding these distinctions is crucial for accurate diagnosis approaches.

Duration time
| 06:20 minutes


Beyonttra®▼ (acoramidis) Prescribing Information

Session 2: Red Flags & Diagnosis

  • Prof. Tschöpe highlights the key red flag signs and symptoms associated with ATTR-CM that healthcare providers should be vigilant about. He discusses the importance of early recognition and the diagnostic tools available to confirm the presence of amyloidosis. This section aims to equip clinicians with the knowledge needed to identify patients who may benefit from further evaluation.

Duration time
| 16:14 minutes

Session 3: Cardiac Diagnosis

  • In this section, Prof. Tschöpe focuses on the cardiac manifestations of ATTR-CM and the diagnostic techniques used to assess cardiac involvement. He covers echocardiography and other imaging modalities, explaining how these tools can help in the accurate assessment of cardiac function in patients with amyloidosis.

Duration time
| 14:35 minutes

Beyonttra®▼ (acoramidis) Prescribing Information

Session 4: Treatment Landscape in ATTR-CM

  • Prof. Tschöpe provides an overview of the current treatment options available for ATTR-CM, discussing both standard therapies and emerging treatments.

Duration time
| 09:22 minutes

Session 5: ATTR-CM Progression

  • In the final section of the masterclass, Prof. Tschöpe addresses the progression of ATTR-CM and the factors that influence disease outcomes. He discusses the importance of ongoing monitoring and the need for individualized treatment plans to manage disease progression effectively.

Duration time
| 06:04 minutes


Beyonttra®▼ (acoramidis) Prescribing Information

 

PP-PF-CAR-IE-0018-1 | April 2026